Mikhail Blagosklonny – The Face of Research on Oncology and Aging

Human beings have always fantasized about being immortal. Decades ago, the idea that people could deter aging seemed absurd—in fact, many scientists termed it as science fiction. That dream, however, is getting closer and closer to reality thanks in part to research by scientists such as Mikhail Blagosklonny.

Who Is Mikhail Blagosklonny?

Mikhail Blagosklonny is a professor of oncology based at the Roswell Park Cancer Institute. He is also a renowned scientist who has been pioneering research into the eradication of cancer, aging, and age-related diseases. He has published over 250 papers on his research on diverse online scientific journals including Oncotarget.Mikhail Blagosklonny attended the Pavlov State Medical University of St. Petersburg where he earned his M.D. in Internal Medicine as well as a Ph.D. in Experimental Medicine. Since graduating, Blagosklonny has taught in several institutions, but he has since settled on his position as a senior scientist at Roswell Park Cancer Institute primarily because of its advanced research facilities.

Mikhail Blagosklonny’s Contribution to Research on Aging

Mikhail Blagosklonny has focused his research on Target of Rapamycin (TOR). The TOR-centric model is based on the knowledge that rapamycin is effective in treating a wide range of ordinary and chronic diseases as well as deterring aging. Scientists have greater confidence in the TOR-centric model today than they did in the past primarily because research has advanced rapidly in the past five years.In particular, Evirolimus (a form of rapamycin analog) has been proven to significantly improve immunity in aging humans. In fact, it is the foundation of the controversial “fountain of youth” drug that is projected to delay the effects of aging and improve the general health and well-being of the elderly. Some people are still skeptical about the success of this drug, but those who are confident in it expect it to be revolutionary.

Few Side-Effects

Amazingly, rapamycin has been proven to have minimal side-effects in spite of its efficacy. Usually, major breakthroughs such as this come at a great cost as remedies often come with scary side-effects. However, Mikhail Blagosklonny and fellow researchers have proven that rapamycin has little side-effects even when used on a daily basis.This has made research much easier as more people are willing to volunteer—in fact, even healthy people have volunteered for tests. This is one of the reasons why research has advanced so rapidly over the past decade, and it is expected to advance at an even greater rate in the near future.

Is Immortality Really Feasible

Aging is not entirely to blame for death—in fact, more people die from other causes other than aging. Some of the leading causes of death include diseases and accidents. As such, immortality is not feasible even with the current breakthroughs.However, people can expect to live longer and healthier lives thanks to the TOR-centric model. After all, scientists argue that the human race would be unsustainable without death. That, however, has not been a deterrent as researchers are stepping up their efforts in this field and related fields such as oncology.

Dr. Clay Siegall Leads Seattle Genetics to Success


Clay Siegall, the president and CEO of a leading biotechnology company called Seattle Genetics, helped to found the company in 1998. He also serves as the chairman of the Board of Trustees and is responsible for leading the capital fundraising efforts to get the company off the ground at a rapid pace. Seattle Genetics had been a trailblazer in the field of antibody cancer therapies. In particular, Seattle Genetics recently secured accelerated approval from the U.S. Food and Drug Administration (FDA) in 2011 for ADCETRIS, which is a cutting edge cancer-fighting antibody.

Part of the reason that Dr. Siegall has been so effective at making Seattle Genetics one of the top names in biotechnology and cancer research and development is because he has such an impressive background. After receiving a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland, Dr. Siegall went on to work at the National Institute of Health and the Bristol-Myers Squibb Pharmaceutical Research Institute. He gained invaluable insight into the biotechnology industry along with unparalleled knowledge about viable antibody therapies. In recognition of his extensive experience and specialized knowledge, Dr. Siegall was specifically recruited for a position on the Board of Directors of Alder BioPharmaceuticals.

Seattle Genetics maintains it corporate headquarters in Bothell, Washington, but it has gained international recognition for its work to advance innovative cancer and other autoimmune disease therapies and treatments.  When it comes to developing out of the box and effective treatments for autoimmune diseases, Seattle Genetics is one of the first companies that comes to mind in the industry. Under the vision and leadership of Dr. Siegall, this top notch company is poised to maintain and advance its position as one of the most respected leaders in the field of biotechnology and treatment of autoimmune diseases. 

Learn More about Clay Siegall: